| Literature DB >> 28222204 |
Abstract
Red swamp crayfish is an important model organism for research of the invertebrate innate immunity mechanism. Its excellent disease resistance against bacteria, fungi, and viruses is well-known. However, the antiviral mechanisms of crayfish remain unclear. In this study, we obtained high-quality sequence reads from normal and white spot syndrome virus (WSSV)-challenged crayfish gills. For group normal (GN), 39,390,280 high-quality clean reads were randomly assembled to produce 172,591 contigs; whereas, 34,011,488 high-quality clean reads were randomly assembled to produce 182,176 contigs for group WSSV-challenged (GW). After GO annotations analysis, a total of 35,539 (90.01%), 14,931 (37.82%), 28,221 (71.48%), 25,290 (64.05%), 15,595 (39.50%), and 13,848 (35.07%) unigenes had significant matches with sequences in the Nr, Nt, Swiss-Prot, KEGG, COG and GO databases, respectively. Through the comparative analysis between GN and GW, 12,868 genes were identified as differentially up-regulated DEGs, and 9,194 genes were identified as differentially down-regulated DEGs. Ultimately, these DEGs were mapped into different signaling pathways, including three important signaling pathways related to innate immunity responses. These results could provide new insights into crayfish antiviral immunity mechanism.Entities:
Year: 2017 PMID: 28222204 PMCID: PMC5409774 DOI: 10.1590/1678-4685-GMB-2016-0133
Source DB: PubMed Journal: Genet Mol Biol ISSN: 1415-4757 Impact factor: 1.771
Summary of Illumina sequencing output for the GN and the GW.
| Sample | Total raw reads | Total clean reads | Total clean nucleotides (nt) | Q20 percentage | N percentage | GC percentage |
|---|---|---|---|---|---|---|
| GN-gills | 40,384,330 | 39,390,280 | 3,939,028,000 | 98.02% | 0.00% | 41.52% |
| GW-gills | 34,840,334 | 34,011,488 | 3,401,148,800 | 98.04% | 0.00% | 41.98% |
Summary of the assembly analysis for GN and GW.
| Dataset name | Group normal (GN) | Group WSSW-challenged (GW) | ||
|---|---|---|---|---|
| Contigs | Unigenes | Contigs | Unigenes | |
| Total number | 172,591 | 94,479 | 182,176 | 95,959 |
| Total length (nt) | 60,746,050 | 60,823,435 | 57,529,732 | 53,499,561 |
| Mean length (nt) | 352 | 644 | 316 | 558 |
| N50 | 690 | 1,345 | 528 | 1,007 |
| Total consensus sequences | - | 94,479 | - | 95,959 |
| Distinct clusters | - | 10,931 | - | 8,229 |
| Distinct singletons | - | 83,548 | - | 87,660 |
Figure 1Gene ontology (GO) classification of transcripts from the two gill samples (GN and GW). The three main GO categories include biological process (blue), cellular component (red), and molecular function (green).
Figure 2Cluster of orthologous groups (COG) classification of putative proteins.
Top 30 statistically significant KEGG classifications.
| No. | Pathway | Pathway definition | Number of sequences |
|---|---|---|---|
| 1 | path: ko01100 | Metabolic pathways | 3371 (13.33%) |
| 2 | path: ko05146 | Amoebiasis | 1148 (4.54%) |
| 3 | path: ko05110 |
| 1092 (4.32%) |
| 4 | path: ko05016 | Huntington's disease | 973 (3.85%) |
| 5 | path: ko04810 | Regulation of actin cytoskeleton | 950 (3.76%) |
| 6 | path: ko04510 | Focal adhesion | 910 (3.6%) |
| 7 | path: ko03040 | Spliceosome | 894 (3.53%) |
| 8 | path: ko05200 | Pathways in cancer | 879 (3.48%) |
| 9 | path: ko05169 | Epstein-Barr virus infection | 860 (3.4%) |
| 10 | path: ko03013 | RNA transport | 847 (3.35%) |
| 11 | path: ko00230 | Purine metabolism | 781 (3.09%) |
| 12 | path: ko04145 | Phagosome | 643 (2.54%) |
| 13 | path: ko04144 | Endocytosis | 638 (2.52%) |
| 14 | path: ko04270 | Vascular smooth muscle contraction | 633 (2.5%) |
| 15 | path: ko03010 | Ribosome | 632 (2.5%) |
| 16 | path: ko04530 | Tight junction | 616 (2.44%) |
| 17 | path: ko00240 | Pyrimidine metabolism | 616 (2.44%) |
| 18 | path: ko04142 | Lysosome | 610 (2.41%) |
| 19 | path: ko04141 | Protein processing in endoplasmic reticulum | 607 (2.4%) |
| 20 | path: ko05166 | HTLV-I infection | 596 (2.36%) |
| 21 | path: ko05168 | Herpes simplex infection | 593 (2.34%) |
| 22 | path: ko05132 | Salmonella infection | 576 (2.28%) |
| 23 | path: ko03015 | mRNA surveillance pathway | 563 (2.23%) |
| 24 | path: ko04120 | Ubiquitin-mediated proteolysis | 557 (2.2%) |
| 25 | path: ko04010 | MAPK signaling pathway | 542 (2.14%) |
| 26 | path: ko04020 | Calcium signaling pathway | 538 (2.13%) |
| 27 | path: ko05414 | Dilated cardiomyopathy | 524 (2.07%) |
| 28 | path: ko05164 | Influenza A | 517 (2.04%) |
| 29 | path: ko05410 | Hypertrophic cardiomyopathy (HCM) | 495 (1.96%) |
| 30 | path: ko04970 | Salivary secretion | 493 (1.95%) |
Figure 3Comparative analysis of the gene expression levels for two transcript libraries between normal (GN) and WSSV-challenged (GW) crayfish gills. Red dots represent transcripts significantly up-regulated in GW, while green dots represent significantly down-regulated transcripts. The parameters “FDR ≤ 0.001” and “| log2 Ratio| ≥ 1” were used as the threshold to judge the significance of gene expression differences.
Figure 4Gene ontology (GO) classification analysis of differentially expressed genes (DEGs) between GN and GW. The three main GO categories include biological process (blue), cellular component (red), and molecular function (green).
Top 80 differentially expressed pathways between GW and GN.
| No. | Pathway | Number of DEGs | P-value | Pathway ID |
|---|---|---|---|---|
| 1 | Glycolysis / Gluconeogenesis | 99 (1.25%) | 3,78E-199 | ko00010 |
| 2 | RNA transport | 219 (2.77%) | 4.26E-92 | ko03013 |
| 3 | Epithelial cell signaling | 64 (0.81%) | 3.64E-19 | ko05120 |
| 4 | Apoptosis | 73 (0.92%) | 2.29E-17 | ko04210 |
| 5 | Allograft rejection | 3 (0.04%) | 7.15E-15 | ko05330 |
| 6 | Renin-angiotensin system | 31 (0.39%) | 2.42E-14 | ko04614 |
| 7 | p53 signaling pathway | 55 (0.69%) | 1.62E-12 | ko04115 |
| 8 | mTOR signaling pathway | 126 (1.59%) | 2.34E-12 | ko04150 |
| 9 | Endocytosis | 177 (2.24%) | 2.35E-11 | ko04144 |
| 10 |
| 36 (0.45%) | 1.87E-10 | ko05150 |
| 11 | Leishmaniasis | 28 (0.35%) | 4.16E-10 | ko05140 |
| 12 | Protein processing in ER | 249 (3.14%) | 9.51E-10 | ko04141 |
| 13 | Synthesis and degradation of ketone bodies | 12 (0.15%) | 1.05E-09 | ko00072 |
| 14 | Metabolism of xenobiotics by P450 | 50 (0.63%) | 3.28E-09 | ko00980 |
| 15 | Phe, Tyr and Try biosynthesis | 13 (0.16%) | 4.22E-09 | ko00400 |
| 16 | Taurine and hypotaurine metabolism | 5 (0.06%) | 5.99E-09 | ko00430 |
| 17 | Collecting duct acid secretion | 44 (0.56%) | 9.75E-09 | ko04966 |
| 18 | Chronic myeloid leukemia | 43 (0.54%) | 2.35E-08 | ko05220 |
| 19 | Pentose phosphate pathway | 30 (0.38%) | 2.69E-08 | ko00030 |
| 20 | ABC transporters | 112 (1.41%) | 7.07E-08 | ko02010 |
| 21 | Thyroid cancer | 18 (0.23%) | 1.21E-07 | ko05216 |
| 22 | Lysosome | 268 (3.38%) | 2.02E-07 | ko04142 |
| 23 | Morphine addiction | 49 (0.62%) | 2.35E-07 | ko05032 |
| 24 | Valine, leucine and isoleucine biosynthesis | 12 (0.15%) | 2.72E-07 | ko00290 |
| 25 | Melanogenesis | 108 (1.36%) | 5.39E-07 | ko04916 |
| 26 | Butanoate metabolism | 40 (0.51%) | 5.58E-07 | ko00650 |
| 27 | Base excision repair | 45 (0.57%) | 6.18E-07 | ko03410 |
| 28 | Long-term depression | 41 (0.52%) | 6.57E-07 | ko04730 |
| 29 | Hepatitis C | 73 (0.92%) | 2.47E-06 | ko05160 |
| 30 | Mismatch repair | 23 (0.29%) | 3.24E-06 | ko03430 |
| 31 | Salivary secretion | 185 (2.34%) | 3.85E-06 | ko04970 |
| 32 | Histidine metabolism | 38 (0.48%) | 4.50E-06 | ko00340 |
| 33 | Bacterial invasion of epithelial cells | 102 (1.29%) | 1.05E-05 | ko05100 |
| 34 | Amoebiasis | 458 (5.78%) | 1.21E-05 | ko05146 |
| 35 | Propanoate metabolism | 72 (0.91%) | 1.25E-05 | ko00640 |
| 36 | Synaptic vesicle cycle | 85 (1.07%) | 1.39E-05 | ko04721 |
| 37 | Ubiquinone and terpenoid-quinone biosynthesis | 11 (0.14%) | 1.48E-05 | ko00130 |
| 38 | Influenza A | 201 (2.54%) | 1.78E-05 | ko05164 |
| 39 | Retrograde endocannabinoid signaling | 71 (0.9%) | 2.46E-05 | ko04723 |
| 40 | Prostate cancer | 113 (1.43%) | 3.11E-05 | ko05215 |
| 41 | Metabolic pathways | 1189 (15.02%) | 3.81E-05 | ko01100 |
| 42 | Starch and sucrose metabolism | 52 (0.66%) | 3.95E-05 | ko00500 |
| 43 | Glyoxylate and dicarboxylate metabolism | 50 (0.63%) | 7.25E-05 | ko00630 |
| 44 | Cocaine addiction | 39 (0.49%) | 0.000103 | ko05030 |
| 45 | Endocrine | 97 (1.23%) | 0.000119 | ko04961 |
| 46 | Phenylalanine metabolism | 33 (0.42%) | 0.000136 | ko00360 |
| 47 | HTLV-I infection | 198 (2.5%) | 0.000137 | ko05166 |
| 48 | Chemokine signaling pathway | 116 (1.47%) | 0.000142 | ko04062 |
| 49 | Vasopressin-regulated water reabsorption | 88 (1.11%) | 0.000148 | ko04962 |
| 50 | Endometrial cancer | 42 (0.53%) | 0.00015 | ko05213 |
| 51 | TGF-beta signaling pathway | 65 (0.82%) | 0.000158 | ko04350 |
| 52 | NOD-like receptor signaling pathway | 68 (0.86%) | 0.000224 | ko04621 |
| 53 | Regulation of actin cytoskeleton | 228 (2.88%) | 0.000291 | ko04810 |
| 54 | Transcriptional misregulation in cancer | 116 (1.47%) | 0.000355 | ko05202 |
| 55 | GnRH signaling pathway | 103 (1.3%) | 0.000478 | ko04912 |
| 56 | Glycine, serine and threonine metabolism | 68 (0.86%) | 0.000653 | ko00260 |
| 57 | Citrate cycle (TCA cycle) | 89 (1.12%) | 0.000814 | ko00020 |
| 58 | Pancreatic cancer | 67 (0.85%) | 0.000861 | ko05212 |
| 59 | Cardiac muscle contraction | 95 (1.2%) | 0.000893 | ko04260 |
| 60 | Tyrosine metabolism | 66 (0.83%) | 0.000972 | ko00350 |
| 61 | Sphingolipid metabolism | 31 (0.39%) | 0.00143 | ko00600 |
| 62 | Oocyte meiosis | 203 (2.56%) | 0.001598 | ko04114 |
| 63 | Adipocytokine signaling pathway | 68 (0.86%) | 0.001695 | ko04920 |
| 64 | Gastric acid secretion | 151 (1.91%) | 0.001769 | ko04971 |
| 65 | Peroxisome | 173 (2.18%) | 0.001809 | ko04146 |
| 66 | PPAR signaling pathway | 106 (1.34%) | 0.001873 | ko03320 |
| 67 | Drug metabolism - other enzymes | 44 (0.56%) | 0.001887 | ko00983 |
| 68 | Neurotrophin signaling pathway | 128 (1.62%) | 0.002169 | ko04722 |
| 69 | Tryptophan metabolism | 69 (0.87%) | 0.002208 | ko00380 |
| 70 | Cysteine and methionine metabolism | 45 (0.57%) | 0.002622 | ko00270 |
| 71 | Taste transduction | 26 (0.33%) | 0.003256 | ko04742 |
| 72 | Fatty acid biosynthesis | 2 (0.03%) | 0.003716 | ko00061 |
| 73 | Focal adhesion | 268 (3.38%) | 0.004214 | ko04510 |
| 74 | Glycosphingolipid biosynthesis - ganglio series | 13 (0.16%) | 0.004679 | ko00604 |
| 75 | Huntington's disease | 315 (3.98%) | 0.005037 | ko05016 |
| 76 | Toll-like receptor signaling pathway | 66 (0.83%) | 0.00549 | ko04620 |
| 77 | Insect hormone biosynthesis | 12 (0.15%) | 0.005932 | ko00981 |
| 78 | D-Arginine and D-ornithine metabolism | 13 (0.16%) | 0.007501 | ko00472 |
| 79 | Progesterone-mediated oocyte maturation | 151 (1.91%) | 0.007619 | ko04914 |
| 80 | Pancreatic secretion | 122 (1.54%) | 0.009396 | ko04972 |
Comparison of relative fold change of RNA-Seq and qRT-PCR results between GW and GN.
| Gene name | Protein identity | Fold variation (GW/GN) | |
|---|---|---|---|
| transcriptome | qRT-PCR | ||
| CL3739.Contig3_All | Lysozyme | 53.80 (up) | 20.51 (up) |
| Unigene68353_All | Integral membrane protein | 42.34 (up) | 25.63 (up) |
| Unigene56169_All | Apoptosis-regulated protein | 26.33 (up) | 16.77 (up) |
| CL88.Contig2_All | Serine protease inhibitor | 24.41 (up) | 18.52 (up) |
| CL4190.Contig1_All | Chitin binding-like protein | 7.29 (up) | 16.87 (up) |
| CL1412.Contig2_All | Interleukin enhancer binding factor | 4.83 (up) | 2.46 (up) |
| CL6575.Contig2_All | Anti-lipopolysaccharide factor | 4.11 (up) | 5.63 (up) |
| CL818.Contig4_All | Dicer 2 | 4.09 (up) | 3.48 (up) |
| CL1181.Contig4_All | Integrin | 3.59 (up) | 8.33 (up) |
| CL6415.Contig2_All | Cathepsin C | 3.49 (up) | 7.38 (up) |
| CL2737.Contig2_All | Ras | 3.16 (up) | 8.22 (up) |
| CL2514.Contig2_All | NF-kappa B inhibitor alpha | 0.46 (down) | 0.19 (down) |
| Unigene789_All | Clip domain serine proteinase 3 | 0.47 (down) | 0.66 (down) |
| Unigene31753_All | Tyrosine-protein kinase isoform | 0.36 (down) | 0.17 (down) |
| CL3161.Contig1_All | Phosphoinositide 3-kinase isoform | 0.49 (down) | 0.88 (down) |
Figure 5Significant differentially expressed genes (DEGs) identified by KEGG as involved in the apoptosis signaling pathway. Red boxes indicate significantly increased expression, green boxes indicate significantly decreased expression and blue boxes indicate unchanged expression.
Figure 6Significant differentially expressed genes (DEGs) identified by KEGG involved in the melanogenesis signaling pathway. Red boxes indicate significantly increased expression, green boxes indicate significantly decreased expression, and black boxes indicate unchanged expression.
Figure 7Significant differentially expressed genes (DEGs) identified by KEGG involved in the Toll-like receptors (TLRs) signaling pathway. Red boxes indicate significantly increased expression, green boxes indicate significantly decreased expression, and black boxes indicate unchanged expression.